2025-11-13T11:02:21-06:00 2024-12-31 812950760 SAX LLP 1040 AVENUE OF THE AMERICAS 16TH FLOOR NEW YORK NY 10018 990 2024-01-01 223283911 THE MYELODYSPLASTIC SYNDROMES FOUNDATION MYEL 8006370839 228 PARK AVENUE S PMB 118983 NEW YORK NY 10003 PEGGY ANN TORNEY CEO 8006370839 2025-11-13 1 0 MIKE SCHALL P02024184 2122682804 2025-11-13 2024 2025-03-06 01:10:19Z X MDS FOUNDATION INC PEGGY ANN TORNEY 228 PARK AVENUE S PMB 118983 NEW YORK NY 10003 2058147 0 X WWW.MDS-FOUNDATION.ORG X 1999 NJ ESTABLISHED BY AN INTERNATIONAL GROUP OF PHYSICIANS AND RESEARCHERS TO PROVIDE AN ONGOING EXCHANGE OF INFORMATION RELATING TO MDS. 7 6 11 6 0 0 1558359 1948899 972104 0 32321 3563 22 49664 2562806 2002126 483164 354600 0 0 654897 849590 0 0 602696 2174787 1749678 3312848 2953868 -750042 -951742 5146339 3847112 754614 257739 4391725 3589373 X THE MYELODYSPLASTIC SYNDROMES FOUNDATION (MDSF) IS A GLOBAL NONPROFIT ORGANIZATION DEDICATED TO SUPPORTING PATIENTS AND CAREGIVERS AFFECTED BY MYELODYSPLASTIC SYNDROMES (MDS), A GROUP OF RARE AND LIFE-THREATENING BONE MARROW DISORDERS, AND THE HEALTHCARE PROFESSIONALS WHO CARE FOR THEM.SINCE OUR FOUNDING MORE THAN 30 YEARS AGO, WE HAVE REMAINED STEADFAST IN OUR MISSION TO ADVANCE RESEARCH, PROVIDE CRITICAL EDUCATION AND SUPPORT SERVICES, AND IMPROVE TREATMENT OPTIONS FOR THOSE IMPACTED BY MDS. 0 0 1293090 THE MDS FOUNDATION ADVOCATES ON BEHALF OF INDIVIDUALS AFFECTED BY MYELODYSPLASTIC SYNDROMES (MDS), A RARE AND COMPLEX BLOOD CANCER. THROUGH EDUCATION, AWARENESS, AND PATIENT ENGAGEMENT, WE EMPOWER PATIENTS AND CAREGIVERS TO MAKE INFORMED HEALTHCARE DECISIONS AND ACCESS APPROPRIATE CARE.WE WORK WITH HEALTHCARE PROFESSIONALS, RESEARCHERS, AND INDUSTRY STAKEHOLDERS TO ENSURE THE PATIENT VOICE IS REPRESENTED IN TREATMENT DEVELOPMENT, POLICY DISCUSSIONS, AND CLINICAL GUIDELINES. WE PROVIDE MULTILINGUAL EDUCATIONAL MATERIALS, PATIENT NAVIGATION SERVICES, PUBLIC AWARENESS CAMPAIGNS, AND REFERRALS TO MDS CENTERS OF EXCELLENCE AROUND THE WORLD.THE MDS FOUNDATION ORGANIZES EDUCATIONAL SYMPOSIA IN COLLABORATION WITH PROFESSIONAL ASSOCIATIONS SUCH AS THE AMERICAN SOCIETY OF HEMATOLOGY AND THE ONCOLOGY NURSING SOCIETY. ADDITIONALLY, THE FOUNDATION HOSTS A BIENNIAL INTERNATIONAL MDS CONFERENCE. THESE DYNAMIC AND INFORMATIVE EVENTS ARE DESIGNED FOR HEMATOLOGISTS, HEMATOLOGY NURSES, FELLOWS, PHARMACISTS, AND OTHER HEALTHCARE PROFESSIONALS INVOLVED IN THE CARE AND TREATMENT OF MDS PATIENTS. THE SYMPOSIA AIM TO ADVANCE CLINICAL KNOWLEDGE, PROMOTE BEST PRACTICES, AND FOSTER COLLABORATION ACROSS DISCIPLINES IN ORDER TO IMPROVE TREATMENT OPTIONS AND OUTCOMES FOR PATIENTS. 265207 EDUCATIONAL SYMPOSIA AND A BI-ANNUAL CONFERENCE ARE CONDUCTED FOR SEVERAL SOCIETIES AND ASSOCIATIONS SUCH AS THE AMERICAN SOCIETY OF HEMATOLOGY AND THE ONCOLOGY NURSING SOCIETY. THESE INFORMATIVE AND INTERACTIVE SYMPOSIA ARE AIMED AT HEMATOLOGISTS AND NURSES WORKING IN HEMATOLOGY, AS WELL AS FELLOWS IN HEMATOLOGY, PHARMACISTS WORKING WITH MDS PATIENTS, AND ALLIED HEALTH PROFESSIONALS WORKING IN THE FIELD OF MDS PATIENT CARE AND TREATMENT. 354600 354600 THE MDS FOUNDATION SUPPORTS AND ADVANCES SCIENTIFIC RESEARCH IN MYELODYSPLASTIC SYNDROMES (MDS) THROUGH ITS YOUNG INVESTIGATOR RESEARCH PROGRAM. THE FOUNDATION INVITES EARLY-CAREER INVESTIGATORS TO SUBMIT PROPOSALS FOCUSED ON BASIC SCIENCE OR CLINICAL RESEARCH RELATED TO THE CAUSES, EPIDEMIOLOGY, MOLECULAR BIOLOGY, CYTOGENETICS, MORPHOLOGY, PROGNOSIS, AND MANAGEMENT OF MDS.IN ADDITION TO FUNDING INDIVIDUAL RESEARCH, THE FOUNDATION CONVENES INTERNATIONAL WORKING GROUPS COMPOSED OF LEADING SCIENTISTS AND PHYSICIANS TO COLLABORATIVELY IMPROVE DIAGNOSTIC STANDARDS, PROGNOSTIC TOOLS, AND TREATMENT STRATEGIES.THE MDS FOUNDATION ALSO PLAYS A KEY ROLE IN PROMOTING AWARENESS OF ONGOING CLINICAL TRIALS AND SUPPORTING PATIENT RECRUITMENT EFFORTS. THROUGH ITS GLOBAL NETWORK OF HEMATOLOGISTS AND CENTERS OF EXCELLENCE, THE FOUNDATION HELPS CONNECT ELIGIBLE PATIENTS TO CLINICAL RESEARCH OPPORTUNITIES AIMED AT IMPROVING CARE AND ADVANCING POTENTIAL CURES.THE FOUNDATION MAINTAINS A GLOBAL NETWORK OF HEMATOLOGISTS WHO ARE INFORMED ABOUT ONGOING CLINICAL TRIALS AND CAN REFER ELIGIBLE PATIENTS INTO THESE RESEARCH PROTOCOLS, SUPPORTING THE ADVANCEMENT OF MDS TREATMENT AND CARE. 1912897 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 0 0 0 0 1 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 8 0 1 11 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 7 6 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 0 1 0 0 NJ MA IL TN CA NY X JAMES CHILDRESS PC 3072202892 1740H DELL RANGE BLVD CHEYENNE WY 82009 DR STEPHEN NIMER CHAIRMAN 4.00 X X 0 0 0 SANDY KURTIN TREASURER 4.00 X X 0 0 0 LEA HARRISON SECRETARY 40.00 X X 93316 0 2676 DR PIERRE FENAUX DIRECTOR 4.00 X 0 0 0 DR PETER GREENBERG DIRECTOR 4.00 X 0 0 0 DR LUCA MALCOVATI DIRECTOR 4.00 X 0 0 0 DR MICHAEL SAVONA DIRECTOR 4.00 X 0 0 0 TRACEY IRACA EXECUTIVE DIRECTOR (THROUGH 1/25) 40.00 X 151094 0 4580 ASHLEY R MONCRIEF PATIENT CARE DIRECTOR 40.00 X 136505 0 1198 TANYA RHODES DEVELOPMENT DIRECTOR 40.00 X 124310 0 3717 505225 0 12171 3 0 1 0 0 34020 322273 1592606 1948899 36261 36261 23323 109 55912 -109 -32589 -32698 -32698 0 322273 0 0 MISC REVENUE 900099 49664 49664 49664 2002126 0 0 53227 354600 354600 251666 148662 40734 62270 484813 193716 105669 185428 8629 3126 1979 3524 46123 21387 9185 15551 58359 27061 11622 19676 270466 143618 126848 38797 38797 18135 18135 170582 97508 41876 31198 45507 21102 9062 15343 37916 21673 9308 6935 116547 96839 6096 13612 254381 235399 11732 7250 272 272 258444 257134 453 857 DEVEL. & PROJ. FEES 287547 287547 WALK-A-THON 239924 239924 FINANCE LEASE 6167 3525 1514 1128 BAD DEBT 4993 4993 2953868 1912897 438275 602696 1946015 1342465 1783341 1519828 240534 181299 44841 12659 117665 1861538 1046200 969077 815338 13414 6975 5146339 3847112 740430 250391 14184 7348 754614 257739 X 3735370 3589373 656355 0 4391725 3589373 5146339 3847112 -951742 -615 150005 0 X 0 1 X 1 0 X 3325798 4284275 3024467 2530463 1948899 15113902 3325798 4284275 3024467 2530463 1948899 15113902 3470320 11643582 2543 2252 8487 32321 36261 81864 47667 9274 11523 35972 49664 154100 15349866 0.75850 0.81360 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1861538 1046200 815338 815338 LEASE LIABILITY 7348 7348 X 2001511 -615 -615 2002126 0 2002126 2953868 0 2953868 0 2953868 PART X, LINE 2: THE ORGANIZATION DOES NOT BELIEVE ITS FINANCIAL STATEMENTS INCLUDE ANY MATERIAL, UNCERTAIN TAX POSITIONS. TAX FILINGS FOR PERIODS ENDING DECEMBER 31, 2021 AND LATER ARE SUBJECT TO EXAMINATION BY APPLICABLE TAXING AUTHORITIES. WALK-A-THON 322273 322273 322273 322273 1 YOUNG INVESTIGATOR GRANTS 2 354600 PART I, LINE 2: THE MDS FOUNDATION, INC.'S YOUNG INVESTIGATOR GRANT PROVIDES AN INVESTIGATOR, EARLY IN THEIR CAREER, THE OPPORTUNITY TO INITIATE, CONTINUE OR COMPLETE A PROJECT THAT FOCUSES ON EITHER BASIC OR CLINICAL MANAGEMENT INTO THE CAUSATION, EPIDEMIOLOGY, MOLECULAR BIOLOGY, CYTOGENETICS, MORPHOLOGY, PROGNOSIS AND TREATMENT OF THE MYELODYSPLASTIC SYNDROMES. THE YOUNG INVESTIGATOR GRANT IS A TWO-YEAR RESEARCH GRANT IN THE AMOUNT OF $150,000, PAID IN TWO EQUAL INSTALLMENTS TO THE AWARDEE'S INSTITUTION. X X 0 0 0 0 0 0 0 0 0 TRACEY IRACA EXECUTIVE DIRECTOR (THROUGH 1/25) 151094 0 0 0 0 0 4580 0 0 0 155674 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B THE DRAFT FORM 990 IS PREPARED BY AN INDEPENDENT ACCOUNTING FIRM AND REVIEWED BY THE FOUNDATION'S CEO AND BOARD OF DIRECTORS. PRIOR TO SUBMISSION TO THE IRS, THE FORM 990 IS FORMALLY REVIEWED AND APPROVED BY THE CHAIRMAN OF THE BOARD, THE FINANCE COMMITTEE, AND THE CEO. THE FINAL VERSION IS DISTRIBUTED TO THE FULL BOARD FOR REVIEW AND COMMENT TO ENSURE ACCURACY AND TRANSPARENCY BEFORE IT IS FILED WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C THE BOARD REVIEWS AND SUBMITS A DISCLOSURE OF RELATIONSHIPS STATEMENT TO THE MANAGEMENT OF MDS FOUNDATION, INC. ANNUALLY. FORM 990, PART VI, SECTION B, LINE 15A THE BOARD PERFORMS A SALARY COMPARABILITY ANALYSIS USING THE 990 INFORMATION FOR SIMILAR NONPROFIT ORGANIZATIONS. FORM 990, PART VI, SECTION C, LINE 18 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART VI, SECTION C, LINE 19 NO DOCUMENTS AVAILABLE TO THE PUBLIC.